EP1906917A2 - Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux - Google Patents

Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux

Info

Publication number
EP1906917A2
EP1906917A2 EP06776332A EP06776332A EP1906917A2 EP 1906917 A2 EP1906917 A2 EP 1906917A2 EP 06776332 A EP06776332 A EP 06776332A EP 06776332 A EP06776332 A EP 06776332A EP 1906917 A2 EP1906917 A2 EP 1906917A2
Authority
EP
European Patent Office
Prior art keywords
film
preparation according
preparation
cellulose
antimigraine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06776332A
Other languages
German (de)
English (en)
Inventor
Petra Obermeier
Thomas Kohr
Kai-Thomas Kramer
Karin Klokkers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Publication of EP1906917A2 publication Critical patent/EP1906917A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • the invention relates to a non-spittable, oral, rapidly disintegrating, monolayer film with an antiemetic or antimigraine agent, its preparation and its use.
  • Pharmaceutical dosage forms such as orodispersible tablets that stick in the mouth and disintegrate rapidly are advantageous in many ways. They facilitate the oral administration of drugs to patients with mental illnesses such as schizophrenia, who are difficult to access to other oral dosage forms (e.g., film-coated tablets). Due to mucoadhesiveness and rapid disintegration of the dosage form, it is not possible for the patient to change the dosage form, e.g. in the oral cavity and later spit out again.
  • a disadvantage of orodispersible tablets is their cost-intensive production, which requires a complex lyophilization process; see. e.g. DE 27 44 493, EP 0 793 495 and WO 01/39 836.
  • some active ingredients in film-coated tablets are only conditionally chemically stable.
  • WO 03/101 420 describes films with reduced tendency to mucous membrane adhesion, WO 03/070 227 mucoadhesive films, and Although in each case films with anti-vomiting or migraine that contain a carbon dioxide as an effervescent additive.
  • a disadvantage of a shower additive are the sour taste and the foaming in the mouth.
  • the formulation is very sensitive to moisture. A possible chemical interaction of the effervescent components with the excipients of the formulation is disadvantageous.
  • WO 02/02085 discloses films having a reduced tendency for oral mucosal adhesion and with cavities to reduce the adhesion of the film to the oral mucosa.
  • EP 259749 describes low-dose agents such as antiemetics in a film with water-soluble swelling agent such as celluloses and with glycerol as a film former.
  • the ratio of film former to gelling agent may be 1:18 to 2:11 (i.e., 0.56: 10 to 1.8: 10).
  • WO 04/012720 discloses films with pullulan and sodium alginate as swelling agents and optionally glycerol as film-forming agent and e.g. an antimigraine agent or antiemetic, wherein the ratio of film former to swelling agent is e.g. Can be 1.2: 10 (Example 4).
  • WO 04/096193 describes films with modified starch and, for example, an antimigraine agent, which films can adhere to the oral cavity.
  • Glycerol, olive oil and mannitol are mentioned as film formers and pectin, xanthan gum, pseudoacacia gum, carrageenan and modified starch as gelling agent at a ratio of film former: gelling agents of for example 6.9: 10 (Example 1) and 0.9: 1 ( Example 2).
  • a surfactant is always added.
  • a disadvantage of the use of surfactants is their potential skin or mucous membrane irritant effect. In addition, many of the usual surfactants taste very bitter. Another disadvantage is a possible interaction in the drug uptake in the gastrointestinal tract.
  • the object of the invention is to provide a non-spittable film with an antiemetic or antimigraine agent.
  • the film should be suitable for oral administration of the antiemetic or antimigraine agent.
  • the film should stick in the mouth after contact with liquid or saliva and decay quickly there, for example, dissolved or decomposed under the action of saliva.
  • the active ingredient-containing film should be both chemically and physically stable.
  • the film should be free of the above surfactants, effervescent or taste maskers.
  • the production of the film should be inexpensive.
  • the invention provides a film-like preparation which comprises one or more film formers, one or more gelling agents and one or more active substance (s) from the group formed by antiemetics and antimigraine agents.
  • the film-like preparation is preferably single-layered and preferably substantially free of voids, surfactants, effervescent additives and taste maskers.
  • the film-shaped preparation is preferably a film, in particular a solid film.
  • the film is monolayered and comprises one or more film formers, one or more gel formers, and one or more active agents.
  • the film is substantially free of voids, surfactants, effervescent and taste maskers.
  • the film decomposes rapidly into saliva. It has been found that the preparation according to the invention offers a very advantageous combination of mechanical stability of the film and rapid release of the active ingredient.
  • one embodiment of the invention relates to a single-layered film-like preparation comprising one or more film formers, one or more gelling agents and one or more active ingredients.
  • the film-like preparation is substantially free of voids, surfactants, effervescent and relativesmaskierern.
  • monolayer film-shaped preparation preferably means a solid preparation which is in the form of a monolayer film.
  • single-layered means that the film is present in the form of a single layer, the layer preferably being homogeneous.
  • the film may be flexible or not flexible, but is preferably flexible.
  • the single-layered film-like preparation is substantially free of voids.
  • a cavity is understood to mean a region which is filled with a fluid (a gas and / or a liquid). Such a cavity usually has a diameter of less than 100 microns.
  • a film-like preparation is substantially free of gas bubbles and / or cavities containing a fluid (gas and / or liquid).
  • the single-layered film-like preparation is substantially free of surfactants.
  • substantially free of surfactants this means that the film-like preparation, based to the entire preparation, less than 1 wt .-%, based on the dried preparation, preferably less than 0.1 wt .-% and particularly preferably less than 0.01 wt .-% surfactant.
  • no surfactants are added as a constituent in the preparation of the film-like preparation.
  • a surfactant in the context of this invention is any conventional surfactant, wetting agent or surfactant.
  • the single-layered film-like preparation is substantially free of effervescent additive.
  • substantially free of effervescent additive means that the film-like preparation, based on the total preparation, less than 1 wt .-%, based on the dried preparation, preferably less than 0.1 wt .-% and particularly preferably less than 0, Contains 01 wt .-% effervescent additive.
  • no effervescent additive is added as a constituent in the preparation of the film-like preparation.
  • a shower additive in the context of this invention is a compound which releases a gaseous compound on addition of water, storage, elevated temperature or the like.
  • an effervescent additive is a compound which is in the mouth, e.g. by the action of saliva releases a gaseous compound, such as a carbon dioxide generator.
  • the film-like preparation thus contains no or almost no effervescent additive, such as a carbon dioxide generator.
  • the single-layer film-like preparation is substantially free of taste maskers.
  • the film-form preparation based on the entire preparation, means less than 1% by weight, based on the dried preparation, preferably less than 0.1% by weight, and particularly preferably contains less than 0.01% by weight flavor masker.
  • no taste maskers are added as a component in the preparation of the film-like preparation.
  • a taste masker in the sense of this invention interacts with a bad-tasting substance, which "disguises" its bad taste.
  • a taste masking agent is understood as meaning a substance which serves to cover the bad taste, for example of an active ingredient.
  • the film or the film-like preparation is in particular free of mixtures of the active ingredient with ion exchange resins,
  • the active ingredient is contained in the preparation in free form and not, for example, encapsulated or closed.
  • Another embodiment relates to film-like, single-layered and preferably void-free formulations free of surfactants, effervescent additive and taste maskers from one or more film formers, one or more gelling agents and one or more active substances from the group of antiemetics and antimigraine agents.
  • the antiemetic may be selected from the group consisting of azasetron, batanopride, clebopride, dazopride, dolasetron, domperidone, granisetron, itasetron, levosulpiride, nabilone, ondansetron, pancopride, ramosetron, tropisetron, zatosetron and their pharmaceutically acceptable salts.
  • the antimigraine agent may be selected from the group consisting of sumatriptan, almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan and their pharmaceutically acceptable salts.
  • the preparation according to the invention is free of
  • Taste masking may optionally include sweeteners or flavorings.
  • the active ingredient content in the film may be from 0.1 to 60% by weight and in particular up to 50% by weight and preferably from 20 to 30% by weight and more preferably about 25% by weight, based in each case on the dried one Preparation.
  • One or more film formers from the following group can be provided for the preparation according to the invention:
  • sugar alcohols and their derivatives in particular sucrose, sorbitol, mannitol, xylite, glucose, fructose, lactose and galactose, low molecular weight organic acids, in particular
  • Citric acid succinic acid, malic acid and adipic acid
  • Polyethylene glycol polyethylene glycol dioleate, 1,3-butanediol,
  • film formers from the sorbitol, xyit, polyethylene glycol, Polyethylene glycol dioleate, 1, 3-butanediol, propylene glycol, isopropyl palmitate, dibutyl sebacate, paraffin oil, ethyl cellulose, cellulose acetate and cellulose phthalate.
  • At least one film former is water-insoluble.
  • Particularly preferred water-insoluble film formers are water-insoluble ethyl cellulose, water-insoluble cellulose acetate and water-insoluble cellulose phthalate, and paraffin oil.
  • water-insoluble is preferably defined so that 1 part of a compound (1 part of the film former or of the yellow indingate) in particular according to the German Pharmacopoeia (9th edition of 1 7th 1987) in 30 to 100 parts of water, more preferably in 100 to 1000 parts of water, more preferably in 1000 to 10000 parts of water and more preferably in more than 10000 parts of water is soluble.
  • Water-soluble is preferably defined such that 1 part of a compound (1 part of the film former or of the gelling agent) in particular according to the German Pharmacopoeia (9th edition of 1 7th 1987) in 10 to 30 parts of water, more preferably in 1 to 10 Share and more preferably in less than 1 part of water is soluble.
  • the content of film of film former may be 5 to 70% by weight, preferably 5 to 30% by weight, in each case based on the dried preparation.
  • a film former in the sense of this invention is in particular a compound which gives the film preparation a certain flexibility of the mechanical properties, such as Restoring force, flexural modulus, expansion modulus and the like, gives.
  • At least one gelling agent can be selected from the following group:
  • polymeric carbohydrates in particular cellulose and its derivatives, preferably hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), starch and its derivatives, agar-agar, alginic acid, arabinogalactan, galactomannan, carrageenan, dextran, tragacanth and gum of vegetable origin, synthetic polymers which soluble or swellable in water, in particular polyvinylpyrrolidone, polyvinyl alcohol,
  • Polypeptides in particular gelatin, albumin and collagen, and
  • the content of gelling agent in the film can be from 10 to 70% by weight, preferably from 20 to 50% by weight, based in each case on the dried preparation.
  • a gelling agent for the purposes of this invention is, in particular, a polymeric compound having a molecular weight of less than 60,000 daltons, preferably from 10,000 to 40,000 daltons. Polymer compounds with this molecular weight advantageously favor a rapid disintegration of the preparation.
  • a combination of at least two gelling agents is preferred;
  • one of the gelling agents is water-insoluble.
  • a combination of at least one cellulose derivative and a synthetic polymer is preferred for the preparation according to the invention; more preferably a combination of at least one water-insoluble cellulose derivative, optionally one or more further cellulose derivatives, and a water-soluble synthetic polymer, and more preferably a combination of water-insoluble ethylcellulose and / or hydroxypropylcellulose and / or hydroxypropylmethylcellulose and polyvinylpyrrolidone.
  • a combination of at least two cellulose derivatives is preferred, of which at least one is water-insoluble, in particular a combination of hydroxypropylcellulose and / or hydroxypropylmethylcellulose and water-insoluble ethylcellulose.
  • the preparation according to the invention may contain at least one sweetener, flavoring agent, preservative, colorant and / or filler, preference being given to a content of from 0.1 to 30% by weight, more preferably from 1 to 15% by weight, based in each case on dried preparation.
  • the preparation according to the invention may e.g. have a film thickness of 1 to 500 microns, preferably 1 to 300 microns.
  • the preparation according to the invention can be in the form of a round, rounded, oval, ellipsoidal, triangular, quadrangular or polygonal film form.
  • the inventive film or the inventive preparation with a smooth surface or surface with Elevations and / or depressions may be provided.
  • the surface may have a regular pattern of protrusions and depressions, such as a wave pattern or a grid pattern.
  • the film or the preparation according to the invention can be provided on a carrier film.
  • the film or the preparation according to the invention with a carrier film of polyethylene paper (PE paper), polypropylene film (PP film) or
  • PET film Polyethylene terephthalate film
  • the film or preparation according to the invention is preferably provided on a carrier film of polyethylene paper (PE paper), polypropylene film (PP film) or polyethylene terephthalate film (PET film).
  • PE paper polyethylene paper
  • PP film polypropylene film
  • PET film polyethylene terephthalate film
  • the film or the preparation according to the invention may be provided for oral administration.
  • an embodiment of the invention relates to a sachet bag with one or more films or preparations according to the invention.
  • the invention relates to a multidose container with one or more films or preparations according to the invention.
  • a single-layer film or a single-layer preparation with one or more film formers, one or more gelling agents and one or more neuroleptics, such as olanzapine a significantly higher chemical stability compared to, for example, olanzapine-containing film-coated tablets.
  • the film adheres to the oral cavity and disintegrates within a few seconds.
  • the film is dissolved or decomposed by saliva, for example, a water-soluble film is dissolved.
  • the film is no longer ausspuckbar.
  • the active ingredient is swallowed predominantly and absorbed in the gastrointestinal tract.
  • the active ingredient can be partially absorbed transmucosally, but this is negligible.
  • the film is preferably substantially free of voids, surfactants, effervescent additives or taste maskers.
  • the preparation of the films is much cheaper compared to so-called orodispersible tablets, for the production of which a complex lyophilization process is required.
  • the preparation according to the invention preferably comprises at least two film formers.
  • the preparation according to the invention preferably comprises at least two gelling agents. Particularly preferred is a combination of at least two gel formers, wherein one of the gelling agent is preferably water-insoluble.
  • the preparation according to the invention comprises one or more
  • Cellulose derivative (s) and a synthetic polymer in particular a water-insoluble cellulose derivative and a water-soluble synthetic polymer.
  • the preparation additionally comprises one or more further film formers selected from the group consisting of sorbitol, polyethylene glycol, polyethylene glycol dioleate, 1,3-butanediol, propylene glycol, isopropyl palmitate, dibutyl sebacate, xylitol and paraffin oil.
  • the preparation additionally preferably comprises one or more further gel formers, in particular one or more further cellulose derivatives, more preferably one or more cellulose derivatives having a molecular weight of less than 60,000 daltons, and particularly preferably hydroxypropylcellulose and / or hydroxypropylmethylcellulose.
  • Such a combination of at least one water-insoluble compound and at least one water-soluble compound results in that the film-like preparation advantageously quickly releases the active ingredient and at the same time has sufficiently high stability.
  • the preparation according to the invention comprises a plurality of cellulose derivatives, one of which is water-insoluble, in particular hydroxypropylcellulose and / or hydroxypropylmethylcellulose and water-insoluble ethylcellulose, and one or more compounds selected from the group consisting of sorbitol, polyethylene glycol, polyethylene glycol dioleate, 1 , 3-butanediol, propylene glycol, isopropyl palmitate, dibutyl sebacate, xylite and paraffin oil.
  • sorbitol polyethylene glycol, polyethylene glycol dioleate, 1 , 3-butanediol, propylene glycol, isopropyl palmitate, dibutyl sebacate, xylite and paraffin oil.
  • Gelling agents may be present in the ratio of 0.5: 10 to 350: 10, preferably 0.7: 10 to 70:10, more preferably 3:10 to 50:10, especially 5:10 to 30:10, and especially preferably 10:10 to 15:10.
  • the films may contain one or more antiemetics, eg azasetron, batanopride, clebopride, dazopride, dolasetron, domperidone, granisetron, itasetron, levosulpiride, nabilone, ondansetron, pancopride, ramosetron, tropisetron, zatosetron and / or their pharmaceutically acceptable salts.
  • antiemetics eg azasetron, batanopride, clebopride, dazopride, dolasetron, domperidone, granisetron, itasetron, levosulpiride, nabilone, ondansetron, pancopride, ramosetron, tropisetron, zatosetron and / or their pharmaceutically acceptable salts.
  • triptans such as sumatriptan, almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, zolmitriptan and / or their pharmaceutically acceptable salts can be used.
  • the active ingredient content in the film can be from 0.1 to 60% by weight and in particular up to 50% by weight, preferably 25% by weight, in each case based on the dried preparation.
  • the film may contain sweeteners, flavorings, preservatives (e.g., sorbic acid or its salts), dyes and / or fillers.
  • Suitable sweeteners are sucralose, aspartame, cyclamate, saccharin and / or acesulfame, or combinations of these substances.
  • flavoring agents natural or artificial flavorings, for example lemon, orange, strawberry, vanilla, peppermint, cinnamyl acetate, citral, citronella, eugenyl, menthol and / or methylanisole can be used.
  • dyes pharmaceutically customary dyes and pigments can be used, in particular TiO 2 , Fe x O x , beta-carotene, azorubin, indigotin, riboflavin and the like.
  • fillers salts such as carbonates, phosphates, oxides, such as SiC> 2 , in particular in the form of Aerosil, or the like and / or cellulose and its derivatives, but also sparingly soluble sugars or sugar derivatives, such as lactose or starch derivatives such as Cyclodextrins, provided that they are present in the product substantially undissolved and thus meet the mechanical properties of a filler.
  • SiO 2 is preferably used as filler.
  • the thickness of the film may be 1 to 500 ⁇ m, preferably 1 to 300 ⁇ m. To avoid an unpleasant feeling in the mouth, the film thickness must not be too large.
  • the films can have round, oval, elliptical, triangular, quadrilateral or polygonal shapes, but they can also have an arbitrarily rounded shape.
  • the surface of the films may be smooth or provided with protrusions or depressions.
  • the disintegration time of the films in the oral cavity is less than 200 seconds, preferably 10 to 60 seconds, especially 10 to 30 seconds.
  • the active ingredient (s) are suspended or dissolved in a solvent.
  • a solvent alcohols or alcohol / water mixtures can be used.
  • the mixture is homogenized.
  • the mixture will brushed onto a substrate using a suitable brushing method.
  • support material for example, PE paper, PP or PET film can be used.
  • the coated support material is dried at 30 to 120 ° C., preferably at 30 to 70 ° C.
  • the coated carrier material is further processed into areal divided, divided films. This can be done by punching, cutting or embossing.
  • the films are individually wrapped in sachet bags with or without carrier foil. They can also be packaged in multidose containers. If necessary, the active substance-containing film is removed from the carrier material prior to ingestion.
  • the film-like preparation according to the invention is used for the administration of antiemetics in the treatment of nausea and vomiting caused by cytostatics and radiotherapy, the treatment of postoperative nausea and vomiting, and the like.
  • the film-like preparation according to the invention is used for the administration of antimigraine agents in the acute treatment of migraine attacks with and without aura, and the like.
  • the film-form antiemetic composition is used for the manufacture of a medicament for the treatment of nausea and vomiting caused by cytostatics and radiotherapy, the treatment of postoperative nausea and vomiting, and the like.
  • the film-form antimigraine preparation is used for the manufacture of a medicament for the acute treatment of migraine attacks with and without aura, and the like.
  • the D-sorbitol is first dissolved in water.
  • 1, 3-butanediol, isopropyl palmitate, paraffin oil and ethanol are added as a solvent and stirred.
  • the ethyl cellulose and the hydroxypropylmethyl cellulose are added and dissolved, and then the naratriptan is weighed and the resulting suspension is homogenized with a suitable stirrer.
  • the mixture is spread using a coating machine on a suitable support, for example PE film and at 50 0 C, the ethanol / water mixture removed.
  • the film thus obtained is then punched out according to the dosage and packaged.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation filmogène monocouche sans cavités et exempte de tensioactifs, d'additifs effervescents et d'agents de masquage de goût, cette préparation comprenant une ou plusieurs substances filmogènes, un ou plusieurs gélifiants et un ou plusieurs principes actifs choisis dans le groupe des antiémétiques et antimigraineux.
EP06776332A 2005-07-20 2006-07-20 Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux Withdrawn EP1906917A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033942A DE102005033942A1 (de) 2005-07-20 2005-07-20 Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für Antiemetikum oder Antimigränemittel
PCT/EP2006/007176 WO2007009800A2 (fr) 2005-07-20 2006-07-20 Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux

Publications (1)

Publication Number Publication Date
EP1906917A2 true EP1906917A2 (fr) 2008-04-09

Family

ID=37156007

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06776332A Withdrawn EP1906917A2 (fr) 2005-07-20 2006-07-20 Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux

Country Status (12)

Country Link
US (1) US20080213343A1 (fr)
EP (1) EP1906917A2 (fr)
JP (1) JP2009501751A (fr)
CN (1) CN101287444A (fr)
AU (1) AU2006271864A1 (fr)
BR (1) BRPI0613871A2 (fr)
CA (1) CA2615552A1 (fr)
DE (1) DE102005033942A1 (fr)
MX (1) MX2008000848A (fr)
RU (1) RU2008105825A (fr)
WO (1) WO2007009800A2 (fr)
ZA (1) ZA200800975B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2248519T3 (en) 2006-10-02 2018-01-02 Applied Pharma Res Non-mucoadhesive film dosage forms
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
US20090148393A1 (en) * 2007-12-11 2009-06-11 Avon Products, Inc. Multistep Cosmetic Compositions
EP3090743A1 (fr) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
CN101849925B (zh) * 2009-06-12 2012-04-18 上海现代药物制剂工程研究中心有限公司 苯甲酸利扎曲普坦膜剂
EP2451274B1 (fr) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Compositions pharmaceutiques
CN102048711B (zh) * 2009-11-11 2013-06-05 河北奥星集团药业有限公司 一种格拉司琼膜制剂及其制备方法
RU2560693C2 (ru) * 2010-03-23 2015-08-20 Апр Эпплайд Фарма Рисерч, С.А. Быстро растворяющиеся системы, освобождающие лекарственные препараты
EP2566467A1 (fr) 2010-05-07 2013-03-13 Hexal Aktiengesellschaft Film muqueux contenant deux produits de substitution du sucre
DE102010049706A1 (de) 2010-10-28 2012-05-03 Hexal Ag Herstellung orodispersibler Filme
DE102010049708A1 (de) 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
US20140364552A1 (en) * 2011-12-09 2014-12-11 Dic Corporation Aqueous resin composition comprising film-forming aid, and steel sheet surface treatment agent containing the same
ITMI20121628A1 (it) * 2012-09-28 2014-03-29 Pharmafilm Srl Film orodisperdibili autosupportanti a rapida dissoluzione per uso terapeutico o alimentare
US10413516B2 (en) 2013-05-09 2019-09-17 Cure Pharmaceutical Corporation Thin film with high load of active ingredient
CN106659751B (zh) * 2014-07-17 2020-12-25 赫克萨尔股份公司 口腔可分散膜
WO2015001541A2 (fr) 2014-09-25 2015-01-08 Shilpa Medicare Limited Composition de film pharmaceutique
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
DE102017103346A1 (de) 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
US20210299202A1 (en) * 2018-07-10 2021-09-30 Cardinal Advisory Limited Formulation of cannabinoid compounds
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US20030118653A1 (en) * 2001-07-06 2003-06-26 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
US20040247649A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
WO2005016321A1 (fr) * 2003-08-15 2005-02-24 Qlt Usa, Inc. Systeme adhesif, biodegradable d'administration de medicament par les muqueuses
WO2005031675A1 (fr) * 2003-09-30 2005-04-07 Koninklijke Philips Electronics, N.V. Telecommande universelle a identification des appareils commandes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007009800A2 *

Also Published As

Publication number Publication date
US20080213343A1 (en) 2008-09-04
BRPI0613871A2 (pt) 2011-02-15
DE102005033942A1 (de) 2007-02-22
CN101287444A (zh) 2008-10-15
JP2009501751A (ja) 2009-01-22
CA2615552A1 (fr) 2007-01-25
WO2007009800A2 (fr) 2007-01-25
RU2008105825A (ru) 2009-10-20
MX2008000848A (es) 2008-03-26
WO2007009800A3 (fr) 2007-06-28
AU2006271864A1 (en) 2007-01-25
ZA200800975B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
EP1904029B1 (fr) Film a decomposition rapide, qui est oral et ne degorge pas comprenant de l'olanzapine
EP1906917A2 (fr) Film oral a decomposition rapide ne pouvant pas etre recrache utilise pour des antiemetiques ou antimigraineux
US9937123B2 (en) Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
US10398644B2 (en) Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
EP2161021B1 (fr) Préparation de film médicinal avec une propriété de dissolution rapide et une flexibilité
EP2632429A1 (fr) Formulation pelliculaire pharmaceutique orale pour substances médicamenteuses au goût amer
EP2632443B1 (fr) Préparation de films orodispersibles
WO2019101800A2 (fr) Films à dissolution orale en forme de poche à forte charge en principe actif
Reddy An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review
EP2566467A1 (fr) Film muqueux contenant deux produits de substitution du sucre

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOHR, THOMAS

Inventor name: KRAMER, KAI-THOMAS

Inventor name: OBERMEIER, PETRA

Inventor name: KLOKKERS, KARIN

17Q First examination report despatched

Effective date: 20080610

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1112842

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100320

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1112842

Country of ref document: HK